Weekly Recap | Intellia Therap -7.85%, FDA priority review acceptedWeekly Review·Sep 12 at 06:25 AMNTLA+0.79%
Weekly Recap | Intellia Therap -1.01%, secures $400m debt facility with OrbiMedWeekly Review·Sep 5 at 07:34 AMNTLA+0.79%
Weekly Recap | Intellia Therap +0.23%, consensus target above spotWeekly Review·Aug 29 at 06:04 AMNTLA+0.79%
